Compare WEST & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | XNCR |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | 1393 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.5M | 937.1M |
| IPO Year | N/A | 2013 |
| Metric | WEST | XNCR |
|---|---|---|
| Price | $9.29 | $14.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.00 | ★ $22.33 |
| AVG Volume (30 Days) | 653.9K | ★ 715.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $11.27 | N/A |
| Revenue Next Year | $10.66 | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $3.59 | $6.92 |
| 52 Week High | $9.81 | $18.69 |
| Indicator | WEST | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 71.73 |
| Support Level | $7.50 | $10.94 |
| Resistance Level | $9.81 | $14.54 |
| Average True Range (ATR) | 0.57 | 0.66 |
| MACD | -0.00 | 0.29 |
| Stochastic Oscillator | 77.01 | 99.85 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.